(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/006055 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 47/12* (2006.01)
A61K 9/19 (2006.01) *A61K 47/02* (2006.01)
A61K 39/395 (2006.01) *A61K 47/18* (2006.01)
A61K 47/26 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CN2022/108825

(22) International Filing Date:
29 July 2022 (29.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202110863978.0 29 July 2021 (29.07.2021) CN

(71) Applicants: **SHANGHAI JUNSHI BIOSCIENCES CO., LTD.** [CN/CN]; Floor 13, Building 2, Nos. 36 And 58, Haiqu Road, Pilot Free Trade Zone, Shanghai 201210 (CN). **SUZHOU JUNMENG BIOSCIENCES CO., LTD.** [CN/CN]; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN).

(72) Inventors: **LIU, Hongchuan**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN). **LIU, Peixiang**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN). **DU, Xiaojie**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN). **MENG, Qin**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN). **LIU, Hui**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN). **FENG, Hui**; EAST OF CHANGAN ROAD, WUJIANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, Jiangsu 215002 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Shanghai 200233 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/006055 A1

(54) Title: ANTI-PD-1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF

(57) Abstract: A stable anti-PD-1 antibody pharmaceutical composition and use thereof. The pharmaceutical composition comprises a buffer and an anti-PD-1 antibody or an antigen-binding fragment thereof; wherein the anti-PD-1 antibody or the antigen-binding fragment thereof has a concentration of about 100-250 mg/mL, and comprises an LCDR1, an LCDR2 and an LCDR3 having amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and an HCDR1, an HCDR2 and an HCDR3 having amino acid sequences set forth in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and wherein the pharmaceutical composition has a pH of about 5.0-6.5. An injection comprising the pharmaceutical composition and use of the pharmaceutical composition and the injection in preparing a medicament for treating a disease or disorder by eliminating, inhibiting or reducing PD-1 activity.